Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/48837
Type
PreprintCopyright
Restricted access
Embargo date
2023
Collections
- IOC - Preprint [157]
Metadata
Show full item record
THE INFLAMMATORY CYTOKINE PROFILE ASSOCIATED WITH LIVER DAMAGE IS BROADER AND STRONGER IN CHRONIC HEPATITIS B PATIENTS COMPARED TO ACUTE HEPATITIS B PATIENTS
Citocinas
Inflamação
Biomarcador
Hepatite B
Paciente
Plasma
Quimiocinas
Author
Valiente, Alexandra Johnson
Liem, Kin Seng
Schwarz, Kathleen B.
Rosenthal, Philip
Murray, Karen F.
Mogul, Douglas
Teckman, Jeffery
Rodriguez-Baez, Norberto
Schwarzenberg, Sarah Jane
Feld, Jordan J.
Wong, David K.
Lewis-Ximenez, Lia L.
Lauer, Georg
Hansen, Bettina E.
C. Ling, Simon
Janssen, Harry L.A.
Gehring, Adam J.
Liem, Kin Seng
Schwarz, Kathleen B.
Rosenthal, Philip
Murray, Karen F.
Mogul, Douglas
Teckman, Jeffery
Rodriguez-Baez, Norberto
Schwarzenberg, Sarah Jane
Feld, Jordan J.
Wong, David K.
Lewis-Ximenez, Lia L.
Lauer, Georg
Hansen, Bettina E.
C. Ling, Simon
Janssen, Harry L.A.
Gehring, Adam J.
Affilliation
Department of Immunology, University of Toronto. Ontario, Canada / Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam. Rotterdam, The Netherlands.
Division of Pediatric Gastroenterology, University of California San Diego. San Diego, California, USA / Department of Pediatrics, Johns Hopkins University. Baltimore, Maryland, USA.
Department of Pediatrics, University of California. San Francisco, San Francisco, California, USA.
Seattle Children's Hospital, Seattle. Washington, USA.
Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, USA,
Department of Pediatrics, Saint Louis University. St. Louis, Missouri, USA.
Department of Pediatrics, University of Texas Southwestern, Dallas, Texas, USA,
Department of Pediatrics, University of Minnesota. Minneapolis, Minnesota, USA.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Institute of Medical Science, University of Toronto. Ontario, Canada.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ, Brasil.
Massachusetts General Hospital. Boston, Massachusetts, USA.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Institute of Health Policy, Management and Evaluation, University of Toronto. Toronto, Ontario, Canada.
Division of Gastroenterology, Hepatology & Nutrition, the Hospital for Sick Children. Toronto, Ontario, Canada / Department of Paediatrics, University of Toronto. Toronto, Ontario, Canada.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Institute of Medical Science, University of Toronto. Ontario, Canada.
Department of Immunology, University of Toronto. Ontario, Canada / Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Institute of Medical Science, University of Toronto. Ontario, Canada.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam. Rotterdam, The Netherlands.
Division of Pediatric Gastroenterology, University of California San Diego. San Diego, California, USA / Department of Pediatrics, Johns Hopkins University. Baltimore, Maryland, USA.
Department of Pediatrics, University of California. San Francisco, San Francisco, California, USA.
Seattle Children's Hospital, Seattle. Washington, USA.
Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland, USA,
Department of Pediatrics, Saint Louis University. St. Louis, Missouri, USA.
Department of Pediatrics, University of Texas Southwestern, Dallas, Texas, USA,
Department of Pediatrics, University of Minnesota. Minneapolis, Minnesota, USA.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Institute of Medical Science, University of Toronto. Ontario, Canada.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ, Brasil.
Massachusetts General Hospital. Boston, Massachusetts, USA.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Institute of Health Policy, Management and Evaluation, University of Toronto. Toronto, Ontario, Canada.
Division of Gastroenterology, Hepatology & Nutrition, the Hospital for Sick Children. Toronto, Ontario, Canada / Department of Paediatrics, University of Toronto. Toronto, Ontario, Canada.
Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Institute of Medical Science, University of Toronto. Ontario, Canada.
Department of Immunology, University of Toronto. Ontario, Canada / Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network. Toronto, Ontario Canada / Institute of Medical Science, University of Toronto. Ontario, Canada.
Abstract
Liver damage in hepatitis B is immune driven and correlates with inflammatory markers in patient serum. There is no comparison of these markers to determine if inflammatory profiles are distinct to different types of liver damage across patients at different stages of disease. We measured 25 inflammatory markers in acute hepatitis B, chronic hepatitis B patients with HBeAg seroconversion and chronic patients stopping nucleoside analogue therapy. Myeloid markers dominated the inflammatory profile in all stages of hepatitis B. More inflammatory markers were detectable in chronic patients, including elevated concentrations of cytotoxic effectors Fas ligand, TRAIL and TNF-a.
Keywords in Portuguese
Vírus da Hepatite BCitocinas
Inflamação
Biomarcador
Hepatite B
Paciente
Plasma
Quimiocinas
Share